Pacira BioSciences PE ratio PCRX

Share price divided by earnings per share over the last twelve months, since 2015.

Today, Oct 23, 2026: 104×
7-year median: 65.6×
Against its 7-year history: 68th; percentile: 0 is its lowest day, 100 its highest
7-year range: 10.0× to 381×
Peer median: 12.5×

Pacira BioSciences' PE ratio is 104× as of Oct 23, 2026: a share price of $36.42 against $0.35 of earnings per share over the last twelve months.

That is above its 7-year median of 65.6×, higher than on 68% of days in the last 7 years.

Over that time it ranged from 10.0× in Aug 2024 to 381× in Jan 2024.

The median for 10 large drugmakers of a similar size is 12.5×.

PE ratio over time

median 65.6×

The dashed line is the 7-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	104×	41.7×	220×
2025	57.6×	47.9×	57.6×
2024	14.2×	10.0×	381×
2023	375×	86.7×	375×
2022	94.2×	44.1×	129×
2021	44.2×	12.3×	45.3×
2020	21.1×	17.8×	23.3×
2019	243×	211×	282×
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	228×	211×	250×
2015	284×	185×	433×

Against its peers

Companies in Drug Manufacturers - General nearest Pacira BioSciences' size, closest first, today.

Company	PE ratio
PCRXPacira BioSciences	104×
ANABAnaptysbio	10.7×
PAHCPhibro Animal Health	15.9×
ANIPANI Pharmaceuticals	15.4×
OMEROmeros	10.9×
AMPHAmphastar Pharmaceuticals	14.8×
HRMYHarmony Biosciences	11.7×
PBHPrestige Consumer Healthcare	13.4×
ABUSArbutus Biopharma	5.4×
NRIXNurix Therapeutics	11.0×
COLLCollegium Pharmaceutical	18.5×
Peer median	12.5×

Where Pacira BioSciences ranks

#35of 41Large drugmakers with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Pacira BioSciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.